Key figures

What does the final I-CARE cohort represent in a few figures ?

For the patients

including patients
0
patient researcher’s actors of this project
contact patient
0
patients contacted for the study purposes
diaries
0
eDiaries sent to patients
reports retrieved
0
eDiaries completed by patients

For the investigators

assessable patients
0
assessable patients
patients years
0
patient – years
resolved queries
0%
of compliance in the ePRO completion
medical reports
0
medical reports collected for the coding
unresolved queries
0%
of unresolved queries on Annual Summaries
An Annual summary is a recap of data collected along 12 months of follow-up coming from a patient's ePRO questionnaires. It is dedicated to investigators and serves for the control quality of data collection from patient declaration.

We did it !!! Analysis in progress. Thanks to all patients, investigators, partners

31/03/2022 : End of Study for all patients
16/05/2022 : last patient out
17/03/2023 : database lock

508 Participating Investigators
305 Study Nurses
22 contributors (GETAID and external contributors)
15 participating countries

Total included population

Total number of included patients :

13 262

  • France : 3757
  • United Kingdom : 2985
  • Italy : 1051
  • Greece : 961
  • Spain : 1026
  • Belgium : 601
  • Germany : 560
  • Denmark : 420
  • Israel : 465
  • Ireland : 389
  • Portugal : 382
  • Hungary : 317
  • Netherland : 139
  • Sweden : 114
  • Poland : 91
europe map gradient v2

Assessable population (= Patients with at least 2 ePro completed)

Repartition of total number of assessable patients per country (10 206 patients)

2022 10 04 15h20 58 1

Repartition of assessable population per treatment (10206 patients)

2022 10 04 15h24 52 1
  • Group 1: Patients having never received biological agents or immunosuppressant (all 5-ASA and steroids formulations are permitted) and then (protocol amendment n°7) patients receiving no ongoing immunosuppressant and biologic agent at inclusion in I-CARE study (all previous medication accepted) (all 5-ASA and steroids formulations are permitted)
  • Group 2: Patients receiving thiopurines alone
  • Group 3: Patients treated with anti-TNF therapy alone without any concomitant immunosuppressant
  • Group 4: Patients treated with anti-TNF therapy in combination with thiopurines or methotrexate
  • Group 5a: Patients treated with vedolizumab alone (without any concomitant immunosuppressant)
  • Group 5b: Patients treated with vedolizumab in combination with thiopurines or methotrexate.
  • Group 6: Patients treated with ustekinumab with or without any concomitant medications.

I-CARE Flowchart

I-CARE Flowchart

La version de votre navigateur est obsolète et votre appareil est exposé à des risques de sécurité.

Pour profiter d'une expérience optimale sur ce site il est fortement recommandé de mettre à jour votre navigateur ou d'en installer un autre :